Nanjing Chia-tai Tianqing Pharmaceutical
Clinical trials sponsored by Nanjing Chia-tai Tianqing Pharmaceutical, explained in plain language.
-
New drug trial targets bulging eyes in thyroid disease
Disease control Not yet recruitingThis early-stage study is testing an investigational drug called NTB003 for people with moderate-to-severe Thyroid Eye Disease (TED). The main goal is to see if the drug is safe and if it can reduce eye bulging and inflammation. The study will enroll about 74 adults who have had …
Phase: PHASE1, PHASE2 • Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New hope for advanced breast cancer patients who run out of options
Disease control Not yet recruitingThis study is testing if adding a new experimental drug called NTQ1062 to a standard hormone therapy (fulvestrant) works better than the standard therapy alone. It is for people with a specific type of advanced breast cancer that has stopped responding to previous hormone treatme…
Phase: PHASE3 • Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New pill trial offers hope for controlling debilitating blood disease
Disease control Not yet recruitingThis study is testing an experimental oral medication called NTQ5082 for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare and serious blood disease. It will compare NTQ5082 against an existing standard treatment to see if it's better at raising and maintaining hemogl…
Phase: PHASE3 • Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New capsule aims for Long-Term control of rare blood disease
Disease control Not yet recruitingThis study is testing the long-term safety and effectiveness of NTQ5082 capsules for adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare and serious blood disorder. It will follow 78 patients who have already benefited from the treatment in earlier studies. The main goa…
Phase: PHASE3 • Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC